Introduction {#S1}
============

In developing countries, cervical cancer is still the major cause of cancer-related death among women ([@B4]). Nearly all cervical cancers are associated with human papillomavirus (HPV) infection ([@B5]). Although significant progress has been achieved in screening and prevention, the 5-year overall survival (OS) rate for cervical cancer remains around 60% ([@B39]). Radiotherapy and chemotherapy are standard therapies for advanced-stage patients ([@B63]), but with limited success. Recently, remarkable progress in cervical cancer immunotherapy has been made, but positive responses only occur in a small fraction of patients. Such responses are usually dependent on dynamic interactions between tumor cells and other factors within the tumor microenvironment (TME).

Tumor microenvironment contains tumor cells and the surrounding blood vessels, signaling molecules, immune cells, and fibroblasts ([@B27]; [@B52]), etc. The TME can critically influence gene expression in cancer tissues, and is gradually recognized as a key contributor to cancer progression and drug resistance ([@B49]; [@B46]; [@B29]; [@B48]; [@B35]; [@B37]). Cancer cells can create a full range of immunosuppression in the TME to counter the body's anti-tumor immunity and achieve immune escape ([@B55]). Several studies have suggested that tumor-associated macrophages (TAMs), matrix metalloproteinase, transforming growth factor-beta, and interleukin (IL)-2 play key roles in cervical cancer progression and are associated with cancer cell invasion and dissemination ability ([@B59]; [@B72]; [@B44]; [@B60]). A deep understanding of the correlation between TME and prognosis, and exploring new strategies for the treatment are urgently needed for precise therapy improvement of cervical cancer.

With the rapid development of public databases and second-generation sequencing technologies, comprehensive analysis for TME-related prognostic genes has become possible. The Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) algorithm ([@B67]) was developed to predict infiltrating immune and stromal cells within tumor tissues using gene expression data in The Cancer Genome Atlas (TCGA) database. Subsequent studies have involved the ESTIMATE algorithm to glioblastomas ([@B25]), renal cell carcinomas ([@B64]), and colon cancers ([@B1]). However, the utility of the ESTIMATE algorithm in cervical cancer has not been previously investigated. In this study, we screened the expression and interaction of TME-related differentially expressed genes (DEGs) in cervical cancer, predicted their regulatory network, and evaluated the potential therapeutic drugs based on several large public databases ([Figure 1](#F1){ref-type="fig"}). The results might provide useful clues for prospective treatment strategies of cervical cancer.

![The workflow of the current study. TCGA = The Cancer Genome Atlas, GEO = Gene Expression Omnibus, TME = Tumor microenvironment, DEGs = Differentially expressed genes, PPI = Protein-protein interaction, ncRNA = non-coding RNA, TF = Transcription factor.](fgene-11-00727-g001){#F1}

Materials and Methods {#S2}
=====================

Data {#S2.SS1}
----

Gene expression profiles and related clinical materials for cervical cancer were downloaded from the TCGA data portal ([@B58]). The inclusion criteria were ([@B4]) pathologically confirmed cervical cancer, ([@B5]) complete RNA expression data from the patients, and ([@B39]) complete ESTIMATE score, immune score, and stromal score ([@B67]).

For further verification, gene expression profiles and clinical materials of another cohort of cervical cancer patients were downloaded from the Gene Expression Omnibus (GEO) database (GSE52903) ([@B40]). In addition, we also used an online web server (OScc) to verify the prognostic value of targeted genes ([@B61]).

Identification of DEGs and Functional Enrichment Analysis {#S2.SS2}
---------------------------------------------------------

Data analysis was conducted using package limma in R language (version 3.4.0) ([@B50]). A fold change (FC) \> 2 and adjusted *p*-value \< 0.05 were set up to screen DEGs. Heat maps were generated by pheatmap package in R ([@B31]).

Through the Search Tool for Retrieval of Interacting Genes/Proteins (STRING) database (version 11.0), functional enrichment analysis was conducted to identify gene ontology (GO) annotation ([@B54]) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. *P* \< 0.05 was considered to be statistically significant.

Survival Analysis {#S2.SS3}
-----------------

Using the survival and survminer package in R, Kaplan-Meier plots and log-rank tests were performed to elucidate the relationship between 5-year overall survival (OS) rates and DEGs expression levels. Univariate Cox regression was used to assess the effect of clinical parameters and mRNA expression on the survival of cervical cancer patients. *P* \< 0.05 was considered to be statistically significant.

Protein-Protein Interaction (PPI) Network Building and Gene Set Enrichment Analysis (GSEA) {#S2.SS4}
------------------------------------------------------------------------------------------

The PPI network was extracted from the STRING database and visualized by Cytoscape software (version 3.4.0) ([@B51]). To identify densely connected regions, Molecular COmplex Detection (MCODE) in Cytoscape was then involved to extract topology-based clusters.

Using the STRING database and GSEA method, we further retrieved a functional profile of the gene set derived from the PPI network ([@B43]; [@B53]). *P* \< 0.05 was considered to be statistically significant.

Extraction of microRNA (miRNA), Long Non-coding RNA (lncRNA), Transcription Factor (TF), and Drug Interactions {#S2.SS5}
--------------------------------------------------------------------------------------------------------------

We obtained the miRNA -- mRNA and lncRNA-mRNA interactions from the RNA Interactome (RNAInter) database (version RNAInter in 2020) ([@B36]), TF-mRNA interactions from the Transcriptional Regulatory Relationships Unraveled by Sentence-based Text mining (TRRUST) database (version 2.0) ([@B23]), and drug-mRNA interactions from the DrugBank database (version 5.1.1) ([@B34]). RNAInter, TRRUST V2 and DrugBank include the curated confirmed interactions from the literatures.

To construct a muti-factor regulator network, we extracted miRNAs, lncRNAs, TFs, and drugs that had interactions with obtained genes.

Pivot Method {#S2.SS6}
------------

We further screened pivot nodes from obtained interaction pairs using the *phyper()* function in R. The pivot node refers to at least two interacting pairs between the node and a gene, and the significance analysis *p*-value of the interaction between the node and the gene set should be \<0.05 by the hypergeometric test ([@B62]). The obtained pivot miRNAs-mRNAs, lncRNAs-mRNAs, and TFs-mRNAs interactions were visualized by Cytoscape. Pivot drugs-mRNA interactions pairs were also analyzed.

Results {#S3}
=======

Immune Scores Are Significantly Associated With HPV Infection, Histological Type, and Patients' Survival {#S3.SS1}
--------------------------------------------------------------------------------------------------------

Among 304 cases in TCGA, 253 (83.2%) were squamous carcinomas, 47 (15.5%) adenocarcinomas, and 4 (1.3%) adenosquamous carcinomas ([Supplementary Table 1](#TS1){ref-type="supplementary-material"}). Based on the ESTIMATE algorithm, the median of stromal scores was -1047.855 (-2586.99 to 778.01), and the median of immune scores was -246.78 (-1645.63 to 3295.3) ([Figure 2A](#F2){ref-type="fig"}). HPV-positive cases had higher immune scores than HPV-negative cases (*p* \< 0.001) ([Figure 2B](#F2){ref-type="fig"}). Cases of squamous carcinoma had significantly higher immune scores and stromal scores than cases of adenocarcinoma (*p* \< 0.01) ([Figures 2C,D](#F2){ref-type="fig"}).

![The immune score and stromal score are associated with clinicopathologic characteristics and overall survival of cervical cancer patients. **(A)** Distribution of immune scores and stromal scores among 304 cervical cancer samples in TCGA. **(B)** Distribution of immune scores among HPV-negative and HPV-positive cases. **(C)** Distribution of immune scores among cervical cancer subtypes. **(D)** Distribution of stromal scores among cervical cancer subtypes. **(E)** A higher immune score is associated with better overall survival (*p* = 0.02). **(F)** Stromal score is not associated with overall survival (*p* = 0.25). TCGA = The Cancer Genome Atlas, GEO = Gene Expression Omnibus, HPV = Human papillomavirus.](fgene-11-00727-g002){#F2}

To assess the potential relationship of stromal and immune scores with patients' outcome, a total of 304 cervical cancer cases were categorized into high-score and low-score groups by the median expression value. The results revealed that patients with high immune scores had a better survival outcome than those with low scores (*p* = 0.02) ([Figure 2E](#F2){ref-type="fig"}). There was no difference in survival outcomes between the two stromal-score groups (*p* = 0.25) ([Figure 2F](#F2){ref-type="fig"}).

DEG Screening and Functional Analysis Between Low- and High-Immune Score Groups {#S3.SS2}
-------------------------------------------------------------------------------

To determine the relationship between global gene expression profiles and immune scores, 1367 DEGs between the two immune-score groups were identified, including 488 downregulated genes and 879 upregulated genes ([Figure 3A](#F3){ref-type="fig"}).

![Comparison of gene expression profiles between the high- and low-immune score groups. **(A)** In the heat maps, genes with higher expression are shown in red, and genes with lower expression are shown in green; genes expressed at the same level are in black. A total of 879 genes were upregulated and 488 genes downregulated in the high-score group as compared to the low-score group. Biological process **(B)**, cellular component **(C)**, and molecular function **(D)** in gene ontology (GO) analysis for 1367 DEGs. **(E)** Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis for 1367 DEGs. DEG = differentially expressed gene.](fgene-11-00727-g003){#F3}

To further understand the potential biological function of the DEGs, GO annotation and KEGG pathway were analyzed. GO analysis showed that the DEGs were mainly enriched in ingredients such as immunological synapse and T cell receptor complex, and mainly enriched in processes such as immune system process and regulation of immune system process, signaling receptor binding, and leukocyte activation ([Figures 3B--D](#F3){ref-type="fig"}). KEGG pathway enrichment analysis demonstrated that the DEGs were mainly associated with antigen processing and presentation, cytokine-cytokine receptor interaction, chemokine signaling pathway and cell adhesion molecules, etc. ([Figure 3E](#F3){ref-type="fig"}).

Kaplan--Meier plots were further performed for 1367 DEGs. A total of 401 DEGs were significantly related to the 5-year OS ([Figure 4](#F4){ref-type="fig"}) ([Supplementary Table 2](#TS2){ref-type="supplementary-material"}).

![Kaplan--Meier survival curves and log-rank tests showing the correlation of partial immune-related genes **(A--I)** with the 5-year survival rates. High gene expression (red line) was correlated with better outcomes in cervical cancer patients.](fgene-11-00727-g004){#F4}

PPI Networks Construction and Functional Enrichment Analysis {#S3.SS3}
------------------------------------------------------------

To examine the interplay among the prognostic DEGs, we built a PPI network, which was made up of 15 modules and comprised 228 nodes and 1041 edges ([Figure 5A](#F5){ref-type="fig"}). GSEA was used to clarify the main biological functions of 228 node genes. The results showed that they were mainly associated with myeloid leukocyte activation, adaptive immune response regulation, and receptor signaling pathways ([Figure 5B](#F5){ref-type="fig"}).

![PPI network among prognostic genes and functional enrichment analysis. **(A)** The PPI network was made up of 15 modules and included 228 nodes and 1041 edges. The color of a node in the PPI network reflects the log (FC) value of the Z score of gene expression, and the size of the node indicates the number of proteins interacting with the designated protein. **(B)** Enrichment profiles generated with GSEA for the gene set in the PPI network. **(C)** Top three modules in the PPI network. PPI = protein-protein interaction, FC = Fold change, GSEA = gene set enrichment analysis.](fgene-11-00727-g005){#F5}

We selected the top three significant modules for further analysis and named these modules cluster 1, cluster 2, and cluster 3 ([Figure 5C](#F5){ref-type="fig"}). Cluster 1 had 171 edges and 19 nodes in the network. In cluster 2, *HLA-DQB1*, *CD3G*, *CD3D*, *CD4*, *CD3E*, *LCK*, and *ZAP70*, which are critical to the immune response, had higher degree values. In cluster 3, *TNFRSF1B*, which is crucial to immune and inflammatory procession ([@B14]), occupied the module center.

After selecting from the three modules and PPI networks with ≥10 node degrees, we obtained 79 key prognostic DEGs ([Supplementary Table 3](#TS3){ref-type="supplementary-material"}).

Validation of Key Prognostic DEGs in the GEO Database {#S3.SS4}
-----------------------------------------------------

We further validated 79 key DEGs in another cohort of 55 cervical cancer patients from the GEO database. Finally, high expressions of four genes (*CCR7*, programmed cell death-1 \[*PD-1*\], *ZAP70*, and *CD28*) was found to be associated with better 5-year OS in both GEO ([Figures 6A,B](#F6){ref-type="fig"}) and OScc ([Supplementary Figure 1](#FS1){ref-type="supplementary-material"}). In univariate analysis, high expression of *CCR7, PD-1*, and *ZAP70* were related to better survival outcome in both TCGA and GEO ([Supplementary Table 4](#TS4){ref-type="supplementary-material"}).

![Validation of 79 key prognostic DEGs in an independent GEO cohort. **(A)** Kaplan-Meier plots and log-rank tests in the TCGA cohort were performed for 4 validated prognostic DEGs based on high (red line) and low (blue line) gene expression. **(B)** Kaplan--Meier plots and log-rank tests in the GEO cohort were performed for 4 validated prognostic DEGs.](fgene-11-00727-g006){#F6}

Construction of a Multifactor Regulatory Network Based on Key Prognostic DEGs {#S3.SS5}
-----------------------------------------------------------------------------

We extracted interaction pairs of miRNAs, lncRNAs, and TFs with 79 key DEGs and constructed a multifactor regulatory network. The network contained 2295 nodes and 7678 edges (2058 miRNA nodes, 79 lncRNA nodes, 192 TF nodes, and 76 mRNA nodes). To acquire nodes with greater influence on the network, the network was pruned using the pivot method and visualized with Cytoscape. The final network including 31 pivot lncRNAs, 148 pivot miRNAs, 21 pivot TFs, and 75 pivot mRNAs, was identified ([Figure 7](#F7){ref-type="fig"}).

![Multifactor regulatory network of key prognostic DEGs. The network was composed of 148 pivot miRNAs, 31 pivot lncRNAs, 21 pivot TFs, and 75 pivot mRNAs. TF = transcription factor, lncRNA = long non-coding RNAs, miRNA = microRNA.](fgene-11-00727-g007){#F7}

Identification of Potential Predictive Drugs {#S3.SS6}
--------------------------------------------

From DrugBank, we obtained 25020 drug-mRNA interaction pairs. A total of 79 key DEGs were then inputted into the database to predict the potential drugs of the genes, and 149 drug-mRNA interactions were extracted. Pivot method was used to simplify the obtained drugs and a total of 39 pivot drugs were predicted ([Table 1](#T1){ref-type="table"}). For example, Bevacizumab and cetuximab has been reported to target FCGR1A and FCGR2B ([@B24]; [@B6]), and these 2 drugs ([@B42]; [@B73]; [@B56]; [@B47]) have already been approved for clinical treatment of cervical cancer.

###### 

Thirty-nine predicted potential drugs and their targeted DEGs in cervical cancer.

  DrugBank ID   Drug                                                           *p-*value   Gene
  ------------- -------------------------------------------------------------- ----------- -------------------------------------------
  DB00075       Muromonab                                                      \< 0.001    *CD247, CD3D, CD3E, CD3G, FCGR1A, FCGR2B*
  DB00098       Antithymocyte immunoglobulin                                   \< 0.001    *CD4, CD86, FCGR2B, ITGAL*
  DB06681       Belatacept                                                     \< 0.001    *CD80, CD86*
  DB01281       Abatacept                                                      \< 0.001    *CD80, CD86*
  DB00095       Efalizumab                                                     0.001       *FCGR1A, FCGR2B, ITGAL*
  DB00004       Denileukin diftitox                                            0.001       *IL2RA, IL2RG*
  DB12698       Ibalizumab                                                     0.001       *CCR5, CD4*
  DB00111       Daclizumab                                                     0.001       *FCGR1A, FCGR2B, IL2RA*
  DB00074       Basiliximab                                                    0.002       *FCGR1A, FCGR2B, IL2RA*
  DB02010       Staurosporine                                                  0.002       *ITK, LCK, ZAP70*
  DB00005       Etanercept                                                     0.003       *FCGR1A, FCGR2B, TNFRSF1B*
  DB06607       Catumaxomab                                                    0.005       *CD3E, FCGR1A*
  DB00041       Aldesleukin                                                    0.010       *IL2RA, IL2RG*
  DB11767       Sarilumab                                                      0.015       *FCGR1A, FCGR2B*
  DB00112       Bevacizumab                                                    0.019       *FCGR1A, FCGR2B*
  DB00081       Tositumomab                                                    0.019       *FCGR1A, FCGR2B*
  DB00110       Palivizumab                                                    0.019       *FCGR1A, FCGR2B*
  DB00028       Immune Globulin Human                                          0.019       *FCGR1A, FCGR2B*
  DB00087       Alemtuzumab                                                    0.019       *FCGR1A, FCGR2B*
  DB00092       Alefacept                                                      0.019       *FCGR1A, FCGR2B*
  DB00002       Cetuximab                                                      0.022       *FCGR1A, FCGR2B*
  DB00073       Rituximab                                                      0.022       *FCGR1A, FCGR2B*
  DB00078       Ibritumomab tiuxetan                                           0.022       *FCGR1A, FCGR2B*
  DB00108       Natalizumab                                                    0.022       *FCGR1A, FCGR2B*
  DB00056       Gemtuzumab ozogamicin                                          0.022       *FCGR1A, FCGR2B*
  DB00051       Adalimumab                                                     0.022       *FCGR1A, FCGR2B*
  DB00072       Trastuzumab                                                    0.030       *FCGR1A, FCGR2B*
  DB00054       Abciximab                                                      0.030       *FCGR1A, FCGR2B*
  DB01254       Dasatinib                                                      0.022       *BTK, FGR, LCK*
  DB00071       Insulin Pork                                                   0.034       *HLA-DQA2*
  DB00707       Porfimer sodium                                                0.039       *HLA-DQB1*
  DB11714       Durvalumab                                                     0.039       *CD80*
  DB11626       Tasonermin                                                     0.039       *TNFRSF1B*
  DB05943       Resatorvid                                                     0.039       *IL2RG*
  DB04835       Maraviroc                                                      0.039       *CCR5*
  DB09052       Blinatumomab                                                   0.039       *CD3D*
  DB00895       Benzylpenicilloyl Polylysine                                   0.039       *FCER1G*
  DB05501       AMD-070                                                        0.039       *CCR5*
  DB01809       Ter-Butyl-3-P-Tolyl-1h-Pyrazolo\[3,4-D\] Pyrimidin-4-Ylamine   0.039       *HCK*

Discussion {#S4}
==========

Cervical cancer treatment has suffered rapid progress in the past decade. It moves away from drugs that attack tumors broadly toward precise immunotherapy that regulates immune responses against tumors. Identifying effective biomarkers related to tumor immune microenvironment (TIME) and prognosis are urgently needed for better patient management.

By ESTIMATE algorithm, we first found that high immune scores were related to better OS, which is consistent with the results of previous studies showing that immune cells infiltrating the tumor tissue may inhibit cancer cells ([@B12]; [@B22]). The study also found HPV-positive cases had higher immune scores than HPV-negative cases, which might be associated with HPV-related microenvironment components regulation, such as increase of regulatory immune responses and decrease of effector immune responses ([@B71]). A total of 1367 DEGs between the low- and high-immune score groups were identified, and 401 DEGs among them were related to survival outcomes of cervical cancer patients. These genes affect the outcomes of patients mainly by regulating TIME-related biological functions, including immune response regulation, leukocyte activation, chemokine activities, and integrin binding. These processes may shape tumor development and anti-cancer immunity, thus improving prognosis ([@B26]; [@B18]; [@B8]).

A PPI network for 401 prognostic DEGs was constructed to reveal the interplay between DEGs, and 228 node genes were confirmed. The top modules that we selected from the PPI network have been reported to influence angiogenesis, proliferation, invasiveness, and therapeutic efficacy in cervical cancer ([@B65]; [@B69], [@B68]; [@B70]; [@B10]). The GSEA results showed that 228 node genes were highly associated with myeloid leukocyte activation, adaptive immune response regulation, and receptor signaling pathways. Silveira et al. reported that proliferation and accumulation of myeloid-derived suppressor cells might worsen cervical cancer progression and strong infiltration of CD14-positive myeloid cells might prolong survival in cervical cancer patients ([@B21]; [@B16]).

By cross-validation with an independent GEO cohort, we identified four prognostic immune-related genes (*CCR7*, *CD28*, *PD-1*, and *ZAP70*). In previous studies, PD-1 expression was only found on the surface of immune cells, while programmed death receptor ligand-1 (PD-L1) was on cervical cancer cells. Their interaction played critical a role in tumor immune escape ([@B3]). Monoclonal antibodies targeting PD-1/programmed death ligand, such as pembrolizumab, have already been widely assessed in clinical trials and are currently approved for the treatment of advanced cervical cancer ([@B7]; [@B11]; [@B13]; [@B17]). Interestingly, in our results, higher expression of PD-1 was associated with better clinical outcomes. However, recent studies revealed a high intrinsic expression of PD-1 in most tumor cell lines ([@B66]). Combined with our functional enrichment analysis results of DEGs (myeloid leukocyte activation, adaptive immune response regulation, and receptor signaling pathways), we speculated that PD-1 expressed on tumor cells might have different functions, such as immune activation, other than that on immune cells. CCR7 has been reported to influence the lymph node metastasis of cervical cancer, prostate cancer cell migration, and mammary cancer cell stemness ([@B9]; [@B15]; [@B38]). Tyrosine kinase ZAP70 has been identified to play a key role in T cell activation and the immune response ([@B20]; [@B2]; [@B33]).

To explore the molecular mechanisms underlying the differential expression of these genes, we further constructed a TF-lncRNA-miRNA-mRNA regulatory network. We identified 148 pivot miRNAs, 31 pivot lncRNAs, 21 pivot TFs, and 75 pivot mRNAs. In addition, a total of 39 potential drugs for key prognostic DEGs were predicted. Bevacizumab was the first molecular antibody to show survival benefit in advanced cervical cancer, and it improved progression-free survival more than 3.7 months ([@B57]). Cetuximab, an anti-epidermal growth factor receptor monoclonal antibody, is a standard option for the treatment of advanced cervical cancer ([@B41]). Fourteen drugs were identified, including catumaxomab, aldesleukin, trastuzumab, and ibritumomab tiuxetan, all of which have been confirmed for various cancers, including malignant ascites ([@B28]), renal cell carcinoma ([@B19]), gastric cancer ([@B30]), and lymphoma ([@B32]), respectively. Among drug-interactions obtained, Staurosporine has been reported to target ZAP70 ([@B45]), but their interaction in cancer research is still blank.

One limitation of our study is that our predictions were based on analyses of online databases, so further experimental validation is needed. In future research, we will further explore the potential functions and signal pathways of the 79 DEGs (especially *CCR7*, *CD28*, *PD-1*, and *ZAP70*) within cervical cancer TIME. A deeper understanding of the complex molecular mechanism of TIME in cervical cancer may help explain the individual difference in immunotherapy efficiency and help explore new treatment strategies.

Conclusion {#S5}
==========

We identified 79 prognostic TIME-related genes in cervical cancer and validated 4 genes (*CCR7*, *CD28*, *PD-1*, and *ZAP70*). Additionally, a total of 39 potential predicted drugs targeting key prognostic genes were obtained, and they might provide new clues for future treatment management. Further investigation of these genes and related regulatory network might put novel insights into the cervical cancer immunotherapy and prognosis improvement in a comprehensive manner.
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